Bronchogen Dosage, half-life & reference guide
Also known as Ala-Glu-Asp-Leu · AEDL peptide
Reviewed Evidence: EmergingPublished by PepVault
A four-amino-acid peptide from the Russian bioregulator program, which its developers describe as a bioregulator for the airways and lungs. In rats with a COPD-like lung disease, a month of it restored the airway lining and calmed inflammation; in the lab it binds DNA. No human study has been published.
- How often
- Daily
- Half-life
- Unknown
- Evidence
- ●
●●Emerging - Routes
- SubQ, Oral capsules
No human study has tested a dose of Bronchogen: the amounts people run are their own protocol, not a reference.
How it works.
A tetrapeptide, Ala-Glu-Asp-Leu (AEDL), from Vladimir Khavinson's St. Petersburg bioregulator program, which its developers describe as the bioregulator of the bronchi and lungs. In rats given a lung disease like COPD by two months of nitrogen dioxide, a month of Bronchogen restored the airway lining, raised the local immune antibody secretory IgA and the surfactant protein that keeps air sacs open, and calmed neutrophil inflammation, in studies by a St. Petersburg lung research group. In the lab it binds DNA and raised the temperature at which DNA strands separate, which its developers read as a sign it acts on genes. No human study of Bronchogen is indexed on PubMed.
Commonly reported: Little to feel; user reports are few.

Where Bronchogen works.

Immune system
In animals. Raised the local immune antibody secretory IgA and the surfactant protein that keeps air sacs open, and calmed neutrophil inflammation.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Not established (no human data)
- Peak effect
- Not established
- Duration
- Courses of about 10 days (community practice)
Day 1–10Community
No human data to set expectations
Bronchogen has never been studied in people, so any change you notice is yours to judge. Commonly reported: little to feel; some redness or itch where it goes in. A line each day on breathing and energy gives you something honest to compare.
Updated Nov 2026
Day 10–30Animal
What the rat studies measured
In rats with a COPD-like lung disease, a month of Bronchogen restored the airway lining and calmed inflammation in the airways. That is a rat model, and no study has tested it in people with lung disease.
The science
Kuzubova 2015: COPD modelled in rats by 60 days of intermittent NO2; a month of Bronchogen removed goblet-cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, restored ciliated cells and raised secretory IgA. Titova 2017: in the same model, lower neutrophilic inflammation, normalized cytokines and enzymes in lavage fluid, more secretory IgA and surfactant protein B.
Sources- Kuzubova et al. (2015)
- Titova et al. (2017)
Updated Nov 2026
Any dayAnimal
What Bronchogen is built on
A four-amino-acid peptide from the Russian bioregulator program, its peptide for the lungs. Its evidence is two rat studies of a COPD-like disease and lab studies of how it binds DNA; there is no human study.
The science
Khavinson 2021 review (Table 5): AEDL, Bronchogen, regulation of lung cells. Kuzubova 2015 and Titova 2017: rat NO2 model of COPD (a St. Petersburg pulmonology group). Monaselidze 2011: raised DNA melting temperature by 3.1 °C, not specific to A-T or G-C pairs. Fedoreyeva 2011: preferential binding to CTG-containing sequences.
Sources- Khavinson et al. (2021)
- Kuzubova et al. (2015)
- Titova et al. (2017)
- Monaselidze et al. (2011)
- Fedoreyeva et al. (2011)
Updated Nov 2026
With ThymalinCommunity
With the thymus extract
Bronchogen is sometimes run beside other bioregulators, one per organ. If one of them is Thymalin: its own Russian study reported fewer respiratory infections in older adults. No study has given the two together.
The science
Khavinson and Morozov 2003: in 266 older adults followed 6–8 years, acute respiratory infections were 2.0–2.4 times less common with the thymus and pineal extracts than in a control group. Running bioregulators side by side is community practice; this pair has no study.
Sources- Khavinson et al. (2003)
Updated Nov 2026
Day 1 is the day you start it.
No human study of Bronchogen has been published. The effects come from rat studies by a St. Petersburg lung research group and from lab studies of DNA by its developers.
Preliminary research
A typical run.
Run notes
- Cycle
- Run in short courses rather than continuously, like the other bioregulators: community courses run about 10 days, a few times a year. The rat studies gave it for a month. No study in people has tested a course length.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- No timing has been studied.
- Routes
- SubQ injection, Oral capsules
- Stacks
- Thymalin
Safety.
Common side effects
- Injection-site redness or itch
Interactions
No interaction studies exist, including with inhaled medicines for asthma or COPD.
Safety notes
No safety study exists: no human study of Bronchogen is indexed, so nothing is known about its side effects beyond user reports, or about long-term use. Discuss with your clinician before use, particularly during pregnancy or breastfeeding, or with asthma, COPD or another lung condition, which need their own treatment.
Goes with.
One question at a time.
Questions people ask.
What is Bronchogen?
A four-amino-acid peptide from the Russian bioregulator program, which its developers describe as a bioregulator for the airways and lungs. In rats with a COPD-like lung disease, a month of it restored the airway lining and calmed inflammation; in the lab it binds DNA. No human study has been published.
How is Bronchogen dosed in research?
The library carries no reference dose for Bronchogen. No human study has tested a dose of Bronchogen: the amounts people run are their own protocol, not a reference.
How long does Bronchogen last?
The half-life of Bronchogen is unknown (never measured).
What do people report on Bronchogen?
Commonly reported on Bronchogen: little to feel; user reports are few.
Is Bronchogen safe?
The research basis for Bronchogen is emerging: primarily preclinical / limited human data. Common side effects in the library: injection-site redness or itch.
What does Bronchogen stack with?
Common stacks for Bronchogen: Thymalin.
Research.
Reference.
- Cadence
Daily
- Half-life
Unknown
Unknown (never measured)
- Research basis
●
●●EmergingPrimarily preclinical / limited human data
Reviewed How we check the library
